Page last updated: 2024-12-08
cimifugin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cimifugin: isolated from Saposhnikovia divaricatae; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Saposhnikovia | genus | A plant genus of the family APIACEAE that contains saposhnikovans, a type of POLYSACCHARIDES.[MeSH] | Apiaceae | A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 441960 |
CHEBI ID | 3701 |
MeSH ID | M0527055 |
Synonyms (22)
Synonym |
---|
C09000 , |
cimifugin |
37921-38-3 |
(2s)-7-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro[3,2-g]chromen-5-one |
AC1L9C0B , |
AKOS015896760 , |
S9028 |
CS-3794 |
CHEBI:3701 |
AC-34701 |
HY-N0634 |
(2s)-7-(hydroxymethyl)-2-(1-hydroxy-1-methyl-ethyl)-4-methoxy-2,3-dihydrofuro[3,2-g]chromen-5-one |
zinc04097841 |
DTXSID10331690 |
mfcd23105630 |
Q27106170 |
cimitin |
CCG-267533 |
(s)-7-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydro-5h-furo[3,2-g]chromen-5-one |
(2s)-2,3-dihydro-7-(hydroxymethyl)-2-(1-hydroxy-1-methylethyl)-4-methoxy-5h-furo[3,2-g][1]benzopyran-5-one |
MS-24427 |
gtpl12555 |
Research Excerpts
Overview
Cimifugin is an important component of chromones in the dry roots of Saposhikovia divaricata for treating inflammatory diseases.
Excerpt | Reference | Relevance |
---|---|---|
"Cimifugin is an important component of chromones in the dry roots of Saposhikovia divaricata for treating inflammatory diseases. " | ( Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway. Li, J; Liu, A; Tu, Y; Wang, Q; Zhang, B; Zhao, W, 2020) | 3.44 |
"Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating allergy. " | ( Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions. Hong, M; Jiang, G; Jiang, X; Liu, H; Tao, Y; Wang, X; Yu, X, 2017) | 3.34 |
Pharmacokinetics
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" When the dosage of SDE was equal to the pure compound calculated by the amount of cimifugin, it was found to have two maximum peaks while the pure compound only showed one peak in the plasma concentration-time curve." | ( Pharmacokinetics of cimifugin in rat plasma after oral administration of the extract of Saposhnikovia divaricatae root. Determination of cimifugin by high performance liquid chromatography coupled with solid phase extraction. Cao, H; Guan, H; Lv, H; Meng, X; Sun, H; Wang, X; Wang, Z; Zhang, G, 2008) | 0.89 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (21)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (9.52) | 29.6817 |
2010's | 14 (66.67) | 24.3611 |
2020's | 5 (23.81) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.01) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |